$ADXS Merck paid over $700m for a preclinical company Tilos. Our pipeline is worth a lot more than Tilos or previous Amgen's licensing deal. If this comes down to an exclusive licensing deal, it will be 2.5x to 3x of previous Amgen's deal. But invest in their technology platform first since it's heavily discounted. The market forces that we cannot control will dictate whether a buyout or partnership will happen or not, but the probabilities are there❗. πŸ˜‚πŸ‚πŸƒπŸƒπŸƒπŸƒ. You guys already know what I think, so draw your own conclusions. GL! Here's a good read.. bizjournals.com/boston/news...
  • 14
  • 1